Avacta Group Plc
Completion of Acquisition of Oxford Medical Diagnostics Limited
Avacta Group Plc ("Avacta" or the "Company"), announces that the conditional
acquisition of Oxford Medical Diagnostics Limited ("OMD") announced on 14
November 2007 has been completed.
Accordingly, application has been made for 21,954,035 ordinary shares of 0.1
pence each in the capital of Avacta ("Ordinary Shares") issued as the first
element of the consideration for the acquisition of OMD to be admitted to
trading on AIM. Dealings are expected to commence on 20 December 2007,
following which the Company's issued ordinary share capital will comprise
800,432,077 Ordinary Shares. The second element of the consideration,
comprising the issue of a further 21,954,035 Ordinary Shares, will take place
on the agreement of the completion balance sheet.
Prof Alastair Smith, Chief Executive, commented:
"The acquisition of OMD delivers on our long term objectives of providing high
value solutions in clinical diagnostics whilst also contributing a nearer term
revenue stream through industrial gas sensing applications. OMD's technology
and industry relationships are highly synergistic to Avacta and we hope to
capitalise on this across the Group.
"Indeed, based on our own discussions with clinicians, we believe that breath
diagnostics has the potential to create a step change in patient testing and
OMD has a strong intellectual property position in this area having been given
an exclusive licence to a patent granted in the US and with ongoing
applications in other geographies. It's a tremendously exciting opportunity"
14 December 2007
Enquiries:
Avacta Group plc Tel: 0870 835 4367
Alastair Smith, Chief Executive
Nexus Financial Ltd Tel: 020 7451 7050
Nicholas Nelson/Kathy Boate nicholas.nelson@nexusgroup.co.uk
WH Ireland Limited Tel: 0161 832 2174
David Youngman/Robin Gwyn
BankOra Limited - Nominated Broker Tel: 020 7562 4713
Henry Turcan/Michael Brennan
*A Private Investor is a recipient of the information who meets all of the conditions set out below, the recipient:
Obtains access to the information in a personal capacity;
Is not required to be regulated or supervised by a body concerned with the regulation or supervision of investment or financial services;
Is not currently registered or qualified as a professional securities trader or investment adviser with any national or state exchange, regulatory authority, professional association or recognised professional body;
Does not currently act in any capacity as an investment adviser, whether or not they have at some time been qualified to do so;
Uses the information solely in relation to the management of their personal funds and not as a trader to the public or for the investment of corporate funds;
Does not distribute, republish or otherwise provide any information or derived works to any third party in any manner or use or process information or derived works for any commercial purposes.
Please note, this site uses cookies. Some of the cookies are essential for parts of the site to operate and have already been set. You may delete and block all cookies from this site, but if you do, parts of the site may not work. To find out more about the cookies used on Investegate and how you can manage them, see our Privacy and Cookie Policy
To continue using Investegate, please confirm that you are a private investor as well as agreeing to our Privacy and Cookie Policy & Terms.